ClinicalTrials.gg
Active, not recruitingNCT07116876Updated Sep 14, 2026

Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers

An interventional study of Graft Application and Wound Dressing Material in Diabetic Foot Ulcer (DFU) and Lower Extremity, sponsored by LifeNet Health. Active, not recruiting at 17 sites in United States. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by LifeNet Health · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
21 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 381 studies in Diabetic Foot with a site in United States — 66 open to participants now, 84 under way, 3 of them phase 3. Diabetic Foot · United States.

Planned enrollment
97th of 322
120 · median 60
Started
2025
with 29 others
No phase
186 of 381
38 open now
Primary completion
2026-12
later than 44 of 83 live
Registered
354th of 381
by date

Among the 381 studies in Diabetic Foot with a site in United States, this one is the 97th largest by planned enrollment of the 322 interventional ones that give a count, is one of 30 that started in 2025, is one of 186 with no phase, reaches primary completion later than 44 of the 83 other live ones, and was the 354th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

66 of the 381 studies in Diabetic Foot with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 21 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies in Diabetic Foot with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate Matrion™ (LifeNet Health, Inc., Virginia Beach, VA), a placental membrane product, as a treatment for diabetic foot ulcers compared to conventional wound care. Matrion is derived from donated human birth tissue and includes both the amniotic and chorionic layers, along with the trophoblast layer. It is minimally processed using a proprietary decellularization method and terminally sterilized to ensure the membrane is acellular and sterile, making it suitable for surgical applications.

03

Conditions studied

  • Diabetic Foot Ulcer (DFU)
  • Lower Extremity

Keywords

  • diabetic foot ulcer
  • placental membrane
  • lower extremity wound
  • decellularized placental membrane
  • foot diseases
  • foot ulcer
  • conventional wound management
04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be considered eligible to participate in this study, a subject must meet the inclusion criteria listed below:

  1. Be male or female and aged between 21 and 80 years at the time of
  2. Have a diagnosis of Type I or Type II diabetes as defined by the American Diabetes Association and have been on a stable anti-diabetic treatment regimen for at least 30 days before the baseline visit.
  3. Have full-thickness wound of the lower extremity, below the ankle
  4. Have a single target ulcer
  5. Have a wound with an area greater than or equal to 1cm2 and less than 25 cm2 with a depth less than or equal to 9 mm
  6. Have a diabetic foot ulcer that has been present for at least 30 days with a Wagner Classification Grade 1 or 2:

    • Grade 1: superficial diabetic ulcer involving the full skin thickness but not underlying tissues
    • Grade 2: ulcer extension involving ligament, tendon, joint capsule, or fascia, without presence of abscess or osteomyelitis
  7. Have an absence of infection based on Infectious Disease Society of America criteria (assessed at BOTH Screening/Visit 1 and Baseline/Visit 2)
  8. Have an adequate circulation to the affected lower extremity, defined as at least one of the criteria within the previous 60 days:

    • Transcutaneous oxygen measurement at the dorsum of the foot greater or equal to 30 mm Hg
    • Ankle-brachial index (ABI) ranging from 0.8 to 1.2
    • At least biphasic Doppler arterial waveforms at the dorsalis pedis and posterior tibial arteries
  9. Have the ability to comply with off-loading and dressing change requirements
  10. Have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an informed consent form (ICF) approved by an institutional review board (IRB), and agree to abide by the study restrictions and return to the site for the required assessments
  11. Have provided written authorization for use and disclosure of protected health information
  12. Have a of greater than 6 months

Exclusion criteria

Exclusion Criteria:

To be eligible for entry into the study, the subject must not meet any of the exclusion criteria listed below:

  1. Be pregnant or lactating
  2. Subjects with a target wound \<30 days old at Screening whose wound area has decreased in size ≥50% between the Screening and Baseline Visits (assessed at Baseline/Visit 2)
  3. Have a circulating exceeding 12% within 90 days of the Screening Visit (assessed at Screening/Visit 1 for subjects with labs collected \<30 days of screening; assessed at Baseline/Visit 2 for subjects with labs collected at screening)
  4. Have a serum creatinine concentration of 3.0 mg/dL or greater within 30 days prior to screening (assessed at Screening/Visit 1 for subjects with labs collected \<30 days of screening; assessed at Baseline/Visit 2 for subjects with labs collected at screening)
  5. Have a sensitivity to either of the following antibiotics: lincomycin, gentamicin, polymyxin B, or vancomycin
  6. Have a sensitivity to polysorbate 20, N-lauroyl sarcosinate, benzonase or glycerol
  7. Have the wound treated with biomedical or topical growth factors within the previous 30 days before the Screening Visit
  8. Need for any additional concomitant dressing material other than the ones approved for this study
  9. Have clinical signs of an infection at the study ulcer site (assessed at BOTH Screening/Visit 1 and Baseline/Visit 2)
  10. Have the inability to tolerate an off-loading boot
  11. Have a known or suspected disease of the immune system
  12. Have an active or untreated or active, uncontrolled connective tissue disease
  13. Had a treatment with or chemotherapeutic agents, radiotherapy or systemic less than 30 days before the Baseline Visit
  14. Have presence of necrosis, purulence, or sinus tracts that cannot be removed by debridement (assessed at Baseline/Visit 2)
  15. Has undergone a revascularization procedure aimed at increasing blood flow in the treatment target limb less than 4 weeks before the Baseline Visit
  16. Have serum , alanine aminotransferase, or alkaline phosphatase levels greater than three times the normal upper limit within 30 days prior to screening (assessed at Screening/Visit 1 if subject had labs collected \<30 days of screening; assessed at Baseline/Visit 2 if subject had labs collected at screening)
  17. Have active Charcot disease
  18. Have undergone treatment with a living skin equivalent within the last 4 weeks before screening
  19. Have ongoing evidence of peripheral vascular disease, including greater than one nonpalpable pulse on either foot
  20. Have the presence of any condition that in the opinion of the investigator places the subject at undue risk or potentially jeopardizes the quality of the data to be generated
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Other
    Arm 1:

    Matrion

    Other: Graft Application

  • Other
    Arm 2

    Conventional Wound Management

    Other: Wound Dressing Material

Interventions

  • OtherGraft Application

    Place the graft on the debrided DFU and secure. Follow with conventional care wound management (dressings and off-loading). Product may be applied weekly.

    Also known as: Matrion

  • OtherWound Dressing Material

    The wound will be debrided and undergo a moist-wound therapy and will be covered with a gauze that is appropriate for the type of wound (moist or dry). Dressings will cover each wound wound for at least 5 days, but no more than 9 days, (7 days +/- 2 days) until the next study visit. Off-loading of the wound is required.

06

What researchers measure

Primary outcomes

  1. Wound Healing

    Proportion of diabetic foot ulcers that have achieved complete wound closure

    Time frame: 12 Weeks

Secondary outcomes

  1. Speed of Wound Closure

    Time to wound closure measured from the baseline visit to the termination visit

    Time frame: 12 weeks

  2. Change in Wound Area

    Change in wound area over time

    Time frame: 12 weeks

  3. Assessment of Wound Closure Rates in Study Participants

    Number of subjects with a healed wound

    Time frame: 12 weeks

  4. Infection

    Rate of wound infection

    Time frame: 12 weeks

  5. Reoccurrence

    Rate of re-occurrence of wound during follow-up period

    Time frame: 14 weeks

  6. Grafts Used

    Average number of Matrion grafts used per subject

    Time frame: 12 weeks

  7. Incidence of Treatment Emergent Adverse Events

    Collection of adverse events, including changes in vital signs, ABI, and physical exams

    Time frame: 12 weeks

07

Study locations

17 sites
  • Compass Medical Research Center
    Tucson, Arizona 85715, United States
  • Bay Area Foot Care
    Castro Valley, California 94546, United States
  • Limb Preservaion Platform, Inc.
    Fresno, California 93710, United States
  • Center for Clinical Research, Inc
    San Francisco, California 94115, United States
  • Bay Area Foot Care
    San Francisco, California 94117, United States
  • ILD Research Center
    Vista, California 92081, United States
  • Humanity Clinical Research, Corp
    Aventura, Florida 33180, United States
  • Dinamo Research & Diagnostic Center, LLC
    Hialeah, Florida 33015, United States
  • Doctors Research Network, Inc.
    Miami, Florida 33156, United States
  • Independent Clinical Research
    Decatur, Illinois 62521, United States
  • Independent Clinical Research, LLC
    Springfield, Illinois 62704, United States
  • US Foot and Ankle Specialists
    Raleigh, North Carolina 27609, United States
  • Foot and Ankle Institute of the Carolinas
    Rocky Mount, North Carolina 27804, United States
  • Olympus Clinical Research
    Katy, Texas 77450, United States
  • Element Research Group
    San Antonio, Texas 78258, United States
  • Olympus-Alcanza
    Sugar Land, Texas 77479, United States
  • Foot and Ankle Specialists of the Mid-Atlantic
    Salem, Virginia 24175, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 104 industry-sponsored interventional studies with no phase under Diabetic Foot, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 17 months is below that.

Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2025
First posted
Aug 12, 2025
StartActual
Jun 26, 2025
Primary completionEst.
Dec 15, 2026
CompletionEst.
Dec 30, 2026
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07116876
Lead sponsor
LifeNet Health
Responsible party
Sponsor
First posted
Aug 12, 2025
Start date
Jun 26, 2025
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Sep 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion